tbuckley/cabot-search huggingface dataset:
Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial
Authors: S. Peters, E. Felip, U. Dafni, A. Tufman, M. Guckenberger, A. Irigoyen, E. Nadal, A. Becker, H. Vees, M. Pless, A. Martinez-Marti, M. Lambrecht, N. Andratschke, Z. Tsourti, A.-C. Piguet, H. Roschitzki-Voser, M. Rabaglio-Poretti, R.A. Stahel, J.F. Vansteenkiste, D. De Ruysscher
Journal: Annals of Oncology (2019)
Docetaxel for hormone-naïve prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden
Authors: N.W. Clarke, A. Ali, F.C. Ingleby, A. Hoyle, J. Calvert, G. Attard, S. Chowdhury, D. Dearnaley, H. Douis, S. Gillessen, R. Jones, Z. Malik, M.D. Mason, R. Millman, C. Parker, H.L. Rush, A.G. Omlin, M.R. Sydes, M.K.B. Parmar, N.D. James
Journal: Annals of Oncology (2019)
Clinical and analytical accuracy of a 523 gene panel next-generation sequencing (NGS) assay on formalin-fixed paraffin-embedded (FFPE) solid tumour samples
Authors: I. Deras, T. Du, C. Zhao, N. Haseley, A. Yazdanparast, T. Jiang, A. Mentzer, A. Purdy, B. Crain, C. Echegaray, D. Lee, J. Lee, J. Silhavy, K. O’Brien, R. Vijayaraghavan, R. Garcia, R. Haigis, T. Pawlowski, J. Dockter
Journal: Annals of Oncology (2019)
Assessment of prognostic and therapeutic factors in men with breast cancer
Authors: D. Herrero Rivera, M.D.R. Morales Herrero, C. Almeida González, A. Sánchez Camacho-Mejías, I. Carrasco García, J. Benedetti Pedroza, A. Falcon Gonzalez, Á Montaño Periáñez, F.J. Salvador Bofil, M. Ruiz Borrego
Journal: Annals of Oncology (2019)
Evaluation of the Nose-to-Brain Transport of Different Physicochemical Forms of Uranium after Exposure <i>via</i> Inhalation of a UO4 Aerosol in the Rat
Authors: Chrystelle Ibanez, David Suhard, Christelle Elie, Teni Ebrahimian, Philippe Lestaevel, Audrey Roynette, Bernadette Dhieux-Lestaevel, François Gensdarmes, Karine Tack, Christine Tessier
Journal: Environmental Health Perspectives (2019)

Health-risk issues are raised concerning inhalation of particulate pollutants that are thought to have potential hazardous effects on the central nervous system. The brain is presented as a direct target of particulate matter (PM) exposure because of the nose-to-brain pathway involvement. The main cause of contamination in nuclear occupational activities is related to exposure to aerosols containing radionuclides, particularly uranium dust. It has been previously demonstrated that instilled solubilized uranium in the rat nasal cavity is conveyed to the brain via the olfactory nerve.The aim of this study was to analyze the anatomical localization of uranium compounds in the olfactory system after in vivo exposure to a polydisperse aerosol of uranium tetraoxide (UO4) particles.The olfactory neuroepithelium (OE) and selected brain structures-olfactory bulbs (OB), frontal cortex (FC), hippocampus (HIP), cerebellum (Cer), and brainstem (BS)-were microdissected 4 h after aerosol inhalation via a nose-only system in adult rats. Tissues were subjected to complementary analytical techniques.Uranium concentrations measured by inductively coupled plasma mass spectrometry (ICP-MS) were significantly higher in all brain structures from exposed animals compared with their respective controls. We observed that cerebral uranium concentrations followed an anteroposterior gradient with typical accumulation in the OB, characteristic of a direct olfactory transfer of inhaled compounds. Secondary ion mass spectrometry (SIMS) microscopy and transmission electron microscopy coupled with energy-dispersive X-ray spectroscopy (TEM-EDX) were used in order to track elemental uranium in situ in the olfactory epithelium. Elemental uranium was detected in precise anatomical regions: olfactory neuron dendrites, paracellular junctions of neuroepithelial cells, and olfactory nerve tracts (around axons and endoneural spaces).These neuroanatomical observations in a rat model are consistent with the transport of elemental uranium in different physicochemical forms (solubilized, nanoparticles) along olfactory nerve bundles after inhalation of UO4 microparticles. This work contributes to knowledge of the mechanistic actions of particulate pollutants on the brain. https://doi.org/10.1289/EHP4927.
Sixty seconds on . . . killer heatwaves
Authors: Abi Rimmer
Journal: BMJ (2019)

Yes, but that is kind of the point. You may remember that when temperatures were rising this summer the media started warning us that a “deadly” heatwave12 was “claiming victims”3 like some sort of serial killer. The Office for National Statistics has now looked into whether the data back up the headlines.4

Well, the ONS says that England and Wales have seen some of their hottest summers …
Outcomes of Vdpace with Immunomodulator Treatment in Initial and Relapsed/Refractory Multiple Myeloma in a Single Center
Authors: Al-Ola Abdallah, Joseph P. McGuirk, Leyla Shune, Erica Hochard, Neil Dunavin, Zahra Mahmoudjafari, Siddhartha Ganguly
Journal: Blood (2017)
Early response to neoadjuvant chemotherapy (NAC) in combination with regional hyperthermia (RHT) to predict long-term survival for adult-type high-risk soft tissue sarcoma (HR-STS): Results of the EORTC-ESHO intergroup phase III study.
Authors: Rolf D. Issels, Eric Kampmann, Lars Lindner, Nelli Dieterle, Ulrich Robert Mansmann, Jaap Verweij, Thomas Kirchner, Clemens Martin Wendtner, Ruediger Wessalowski
Journal: Journal of Clinical Oncology (2012)

10054 Background: A randomized phase III completed trial showed that RHT added to NAC was beneficial in terms of local progression-free (LPFS), and disease-free (DFS) survival. Overall survival (OS) was improved in patients (pts) who completed the preoperative induction therapy with RHT (Lancet Oncol 2010). Here we analyzed both the radiographic (RR) and histopathologic (HR) response as early predictors for survival. Methods: 341 pts were randomized to receive 4 cycles of NAC + RHT (169 pts) or NAC alone (172 pts) as induction therapy. RR (CR/PR vs NC/PD) and HR (&gt;75% vs &lt;75% necrosis) were used to define responder vs non-responder. Predictive impact of response on LPFS, DFS, DDFS (distant disease-free survival) and OS was evaluated by intention-to-treat using Kaplan-Meier estimates and the log-rank test. Stratified (surgery before study entry yes/no; extremity vs non-extremity tumors) multivariate analyses were carried out by Cox regression. Results: Early response in pts with measurable disease was performed in 238 pts (103 pts not evaluable because of surgery before study entry). In the NAC+RHT group (114 pts) response rate was 49.1% (56 responders: RR: 18; HR: 22; RR + HR: 16) and substantially higher (p&lt;0.001) compared to the NAC alone group (124 pts) which was 26,6% (33 responders: RR: 7; HR: 17; RR + HR: 9). In the NAC + RHT group, tumor response was associated with improved DFS (HR 0.58 CI 0.36-0.95; p=0.031) and OS (HR 0.50 CI 0.27-0.90; p=0.020) but not LPFS (HR 0.91 CI 0.49-1.71; p=0.78). For responders, OS median time was &gt; 120 months vs 33 months for non-responders. For the entire NAC + RHT group (169 pts, including pts with surgery before study entry) response remained predictive for better OS (HR 0.54 CI 0.32-0.94; p=0.028) and was also associated with better DDFS (HR 0.47 CI 0.27-0.83; p=0.009). Conclusions: Adding RHT to NAC as induction therapy compared to NAC alone leads to significantly higher early response in almost half of the pts classified as responders which translates in better OS and prevention of distant metastases.
Evaluation of Donor CD4+CD25+Foxp3+ Regulatory T Cells and CD3-CD56+ NK Cells on Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Fumihito Tajima, Koji Adachi, Takaya Nishio, Toshio Kawatani, Junji Suzumiya
Journal: Blood (2018)
Phase I study of intraperitoneal TRX-E-002-1 in subjects with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer: Three-month follow-up results of the dose escalation phase
Authors: J. Coward, G. Kichenadasse, P. Harnett, K. Moore, M. Barve, D. Berg, J. Garner, D. Dizon
Journal: Annals of Oncology (2019)
Abstract 12290: Exosomal miR-223 Contributes to Mesenchymal Stem Cell-Elicited Cardio-protection in Polymicrobial Sepsis
Authors: Xiaohong Wang, Wei Huang, Yigang Wang, Guo-Chang Fan
Journal: Circulation (2015)

Background: Mesenchymal stem cells (MSCs) have been shown to elicit cardioprotective effects in polymicrobial sepsis induced by cecal ligation and puncture (CLP). However, the underlying mechanisms remain obscure. While recent studies have indicated that miR-223 is highly enriched in MSC-derived exosomes, whether exosomal miR-223 contributes to MSC-mediated cardioprotection in sepsis is unknown. Methods and Results: MSCs harvested from the bone marrow of female pre-miR-223 knockout (KO) and wild-type (WT) mice were injected into male WT mice via the tail vein 1 h after CLP. We observed that the mortality of mice at 32h post-CLP was significantly reduced in WT- MSC-injected mice, but not in KO-MSC-treated groups, compared with controls. CLP-triggered cardiac dysfunction, apoptosis and inflammatory response were also attenuated in mice treated with WT-MSCs, but not miR-223 KO-MSCs. Furthermore, in vitro study showed that WT-MSCs could release miR-223-enrinched exosomes (WT-exosomes) that were taken up by macrophages and cardiomyocytes, leading to reduced production of pro-inflammatory factors (TNF-α, IL-1β, and IL-6) from macrophages and cardiomyocyte death upon LPS insults. By contrast, miR-223-KO-exosomes stimulated macrophage to release these cytokines and increased cardiomyocyte death upon LPS challenge. In vivo study showed that injection of KO-exosomes into the tail vein of mice at 1h post-CLP significantly increased: 1) serum levels of TNF-α, IL-1β, and IL-6; 2) cardiac dysfunction; and 3) animal mortality. Conversely, treatment of mice with WT-exosomes displayed the opposite effects. Mechanistically, we identified that miR-223-KO exosomes contained higher levels of Sema3A and Stat3, two known targets of miR-223 (5p &amp; 3p), than WT-exosomes. Accordingly, these exosomal proteins were able to be transferred to macrophages and cardiomyocytes, leading to increased inflammation and cell death. By contrast, WT-exosomes encased higher levels of miR-223, which could be delivered to macrophages and cardiomyocytes, resulting in down-regulation of Sema3A and Stat3. Conclusions: These data for the first time indicate that exosomal miR-223 plays an essential role for MSC-induced cardioprotection in sepsis.
Recruitment of PKC-Beta to Lipid Rafts Mediates Apoptosis-Resistance in Chronic Lymphocytic Leukemia Expressing Zap-70.
Authors: Ingo Ringshausen, Michaela Wagner, Gloria Lutzny, Madlen Oelsner, Yvonne Feuerstacke, Thomas Decker, Christian Bogner, Christian Peschel, Christian Meyer zum Buschenfelde
Journal: Blood (2009)
Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis
Authors: D.V. Catenacci, H. Park, H. Uronis, Y.-K. Kang, M.C.H. Ng, P. Enzinger, K.W. Lee, K.H. Lim, P.J. Gold, J. Lacy, S.H. Park, K. Huber, A. Wynter-Horton, J. Nordstrom, T. Wu, J. Wigginton, J. Baughman, M. Rosales, J. Davidson-Moncada, Y.-J. Bang
Journal: Annals of Oncology (2019)
Effect of open-lung vs conventional perioperative ventilation strategies on postoperative pulmonary complications after on-pump cardiac surgery: the PROVECS randomized clinical trial
Authors: David Lagier, François Fischer, William Fornier, Thi Mum Huynh, Bernard Cholley, Benoit Guinard, Bob Heger, Gabrielle Quintana, Judith Villacorta, Francoise Gaillat, Romain Gomert, Su Degirmenci, Pascal Colson, Marion Lalande, Samir Benkouiten, Tam Hoang Minh, Matteo Pozzi, Frederic Collart, Christian Latremouille, Marcos F. Vidal Melo, Lionel J. Velly, Samir Jaber, Jean-Luc Fellahi, Karine Baumstarck, Catherine Guidon
Journal: Intensive Care Medicine (2019)
Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
Authors: L. Rimassa, R.K. Kelley, T. Meyer, B.-Y. Ryoo, P. Merle, J.-W. Park, J.-F. Blanc, H.Y. Lim, A. Tran, A.E. Borgman-Hagey, D.O. Clary, E. Wang, A.-L. Cheng, A.B. El-Khoueiry, G.K. Abou-Alfa
Journal: Annals of Oncology (2019)
Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial
Authors: Klemen Dovc, Claudia Piona, Gül Yeşiltepe Mutlu, Natasa Bratina, Barbara Jenko Bizjan, Dusanka Lepej, Revital Nimri, Eran Atlas, Ido Muller, Olga Kordonouri, Torben Biester, Thomas Danne, Moshe Phillip, Tadej Battelino
Journal: Diabetes Care (2019)

OBJECTIVE We evaluated the safety and efficacy of day-and-night fully closed-loop insulin therapy using faster (Faster-CL) compared with standard insulin aspart (Standard-CL) in young adults with type 1 diabetes. RESEARCH DESIGN AND METHODS In a double-blind, randomized, crossover trial, 20 participants with type 1 diabetes on insulin pump therapy (11 females, aged 21.3 ± 2.3 years, HbA1c 7.5 ± 0.5% [58.5 ± 5.5 mmol/mol]) underwent two 27-h inpatient periods with unannounced afternoon moderate-vigorous exercise and unannounced/uncovered meals. We compared Faster-CL and Standard-CL in random order. During both interventions, the fuzzy-logic control algorithm DreaMed GlucoSitter was used. Glucose sensor data were analyzed by intention-to-treat principle with the difference (between Faster-CL and Standard-CL) in proportion of time in range 70–180 mg/dL (TIR) over 27 h as the primary end point. RESULTS The proportion of TIR was similar for both arms: 53.3% (83% overnight) in Faster-CL and 57.9% (88% overnight) in Standard-CL (P = 0.170). The proportion of time in hypoglycemia &amp;lt;70 mg/dL was 0.0% for both groups. Baseline-adjusted interstitial prandial glucose increments 1 h after meals were greater in Faster-CL compared with Standard-CL (P = 0.017). The gaps between measured plasma insulin and estimated insulin-on-board levels at the beginning, at the end, and 2 h after the exercise were smaller in the Standard-CL group (P = 0.029, P = 0.003, and P = 0.004, respectively). No severe adverse events occurred. CONCLUSIONS Fully closed-loop insulin delivery using either faster or standard insulin aspart was safe and efficient in achieving near-normal glucose concentrations outside postprandial periods. The closed-loop algorithm was better adjusted to the standard insulin aspart.
Imaging the Whole Genome in Diagnosing Neurologic Disorders
Authors: Bryce A. Mendelsohn
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)
Authors: P. Nathan, A. Needham, P.G. Corrie, S. Danson, J. Evans, S. Ochsenreither, S. Kumar, A. Goodman, J.M.G. Larkin, I. Karydis, N.M. Steven, P. Lorigan, R. Plummer, P. Patel, H.M. Shaw, S. Leyvraz, C. Rawcliffe, E.E. Psarelli, L. Handley, J.J. Sacco
Journal: Annals of Oncology (2019)
3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)
Authors: C.U. Blank, J.M. Versluis, I.L.M. Reijers, K. Sikorska, W.J. van Houdt, J.V. van Thienen, S. Adriaansz, H.A. Mallo, H. van Tinteren, B.A. van de Wiel, L.G. Grijpink-Ongering, A. Bruining, J B A G Haanen, A.C.J. van Akkooi, T.N. Schumacher, E.A. Rozeman
Journal: Annals of Oncology (2019)
CLINICAL POTENTIAL OF CIRCULATING TUMOR CELLS IN COLORECTAL CANCER: A PROSPECTIVE STUDY
Authors: GA Song, DH Baek, MW Lee, JW Park, SH Lee
Journal: Endoscopy (2019)

Identification of Circulating tumor cells (CTCs) in the peripheral blood has been suggested for an early diagnostic and prognostic marker in patient with colorectal cancer (CRC). However, only limited data exist on the diagnostic impact of CTCs in patients with CRC. In this study, we evaluate a newly developed CTCs detection systems based on the cell size to assess CTCs and its clinical potential with early diagnosis and prognostic biomarker in CRC patient.
Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)
Authors: Y. Kawashima, O. Yamaguchi, T. Kozuki, N. Furuya, F. Kurimoto, T. Okuno, T. Yamada, K. Komiyama, R. Ko, Y. Nagai, N. Ishikawa, T. Harada, K. Watanabe, M. Seike, K. Yoshimura, K. Kobayashi, H. Kagamu
Journal: Annals of Oncology (2019)
CLEPSIDRA trial: A pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer
Authors: A.F. Navarro Mendivil, S. Gutierrez, T. Maes, R. Bullock, M. Ropacki, C. Buesa
Journal: Annals of Oncology (2019)
Longitudinal increase in Ki67 and high-grade transformation in pancreatic neuroendocrine tumours (PNETs)
Authors: J. Botling, A. Lamarca, D. Bajic, O. Norlen, V. Lönngren, J. Kjaer, B. Eriksson, S. Welin, P. Hellman, G. Rindi, B. Skogseid, J. Crona
Journal: Annals of Oncology (2019)
The Cause and Prevention of Anastomotic Recurrence following Colectomy
Authors: M. Arlen, J. Crawford, G. Coppa, O. Saric, J. Bandovic, A. Doubakovski, J. Sullivan, C. Conte, A. Kadison, J. Procaccino, P. Arlen, X. Wang, E. Molmenti
Journal: International Journal of Surgery (2018)
Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Authors: C. Yang, M.A. Iafolla, S. Dashner, W. Xu, A.R. Hansen, P. Bedard, S. Lheureux, A. Spreafico, A.A. Razak, H.-T. Wu, S. Shchegrova, Z.A. Liu, P.S. Ohashi, D. Torti, M. Louie, H. Sethi, A. Aleshin, L.L. Siu, S. Bratman, T.J. Pugh
Journal: Annals of Oncology (2019)
A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Authors: T. Harada, H. Asahina, S. Oizumi, K. Takamura, M. Harada, K. Kanazawa, Y. Fujita, T. Kojima, F. Sugaya, H. Tanaka, H. Ryoichi, T. Ogi, T. Ikari, H. Yokouchi, E. Kikuch, H.D. Akita, H. Isobe, M. Nishimura
Journal: Annals of Oncology (2019)
(-)-Gossypol inhibits zeranol and leptin-induced mcf-7 adr cell proliferation
Authors: Pingping Xu, Weiping Ye, Wei-Cheng Huang, Young Lin
Journal: Cancer Research (2008)

623   Breast cancer is a world-wide disease and it is the second cause of death in cancers in postmenopausal women. One of known risk factors of breast cancer is obesity which has become a major public health concern. The morbidity is increased by 30-50% in obese cancer patients comparing to normal weight cancer patients. Leptin, mainly secreted by adipocytes, is a product of obese  (ob)  gene and plays an important role in breast cancer development. Leptin expression is upregulated in obesity and it can promote breast cancer cell growth by signaling through its receptors and by direct effects on estrogen receptor (ER) pathway. Zeranol (Z) is a mycotoxin produced by fusarium fungus existed in wetted cereals. Z is a non-estrogenic anabolic growth promoter used in the U. S. beef industry. The (-)-Gossypol {(-)-GP} enantiomer, a potent natural polyphenolic agent contained in cottonseed products possesses anticancer and chemopreventive activities. We investigate whether (-)-GP interferes with Z- or leptin-induced MCF-7 Adr cell proliferation. After 24 hours treatment, cell proliferation and mRNA expression levels were analyzed from controls and treated cell samples. Exposure of Z at 30 nM and leptin at 100 ng/ml for 24 hrs significantly increased MCF-7 Adr cell growth. The combined treatment of 30 nM Z and 100 ng/ml of leptin further stimulated the cell proliferation compared to treatment of Z or leptin alone. (-)-GP at 5 µM significantly suppressed the Z- and leptin-induced cell proliferation. Leptin or Z treatment is capable of suppressing the PTP γ, enhancing the cyclin D1 mRNA expression levels. However, (-)-GP treatment reversed the stimulatory effect of Z and leptin’s regulation on PTP γ and cyclin D1 expressions. Z and leptin are capable of stimulating human breast cancer cell growth and (-)-GP suppresses both actions of Z and leptin on human breast cancer cell growth.  Our report is the first to reveal that (-)-GP as a food component in cottonseed products may serve as a potential chemopreventive agent to suppress the stimulatory effect of Z and leptin on human breast cancer cells. (Supported by Grants from NIH R01 ES 015212 and Cotton Inc. Project No. 06-864).
Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Authors: S C F A Huijberts, E. van Brummelen, R. van Geel, F.L. Opdam, S. Marchetti, N. Steeghs, S. Pulleman, B. Thijssen, H. Rosing, K. Monkhorst, A.D.R. Huitema, J.H. Beijnen, R. Bernards, J.H.M. Schellens
Journal: Annals of Oncology (2019)
Association Between Medicare’s Mandatory Joint Replacement Bundled Payment Program and Post–Acute Care Use in Medicare Advantage
Authors: Andrew D. Wilcock, Michael L. Barnett, J. Michael McWilliams, David C. Grabowski, Ateev Mehrotra
Journal: JAMA Surgery (2019)

This study examines how the reduced use of institutional post–acute care in Medicare's Comprehensive Care for Joint Replacement program affected patients who underwent lower extremity joint replacement.
Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation
Authors: M. Popova, Y. Rogacheva, A. Volkova, I. Markova, I. Nikolaev, S. Ignatieva, T. Bogomolova, A. Kozlov, K. Lepik, L. Stelmakh, A. Beynarovich, E. Borzenkova, E. Darskaya, E. Kondakova, N. Mikhailova, S. Bondarenko, I. Moiseev, L. Zubarovskaya, N. Klimko, B. Afanasyev
Journal: Annals of Oncology (2019)
A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment
Authors: L.-T. Chen, E. Hitre, W.-J. Lee, L.-Y. Bai, Z. Papaï, S.Y. KANG, M. Dvorkin, H.J. Choi, S.C. Oh, P. Artru, J.-B. Bachet
Journal: Annals of Oncology (2019)
US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017
Authors: Mallorie H Fiero, Jessica K Roydhouse, Jonathon Vallejo, Bellinda L King-Kallimanis, Paul G Kluetz, Rajeshwari Sridhara
Journal: The Lancet Oncology (2019)